Abstract 155P
Background
Breast cancer is a public health issue both in the world and in Mexico, where 70% of patients with the disease are diagnosed in later stages. Because of this, at Instituto Nacional de Cancerología (The National Cancer Institute), neoadjuvant chemotherapy has become the standard for managing locally advanced breast cancer. However, studies show that less than 50% of patients present a complete pathologic response to this regime, which is why is essential to identify molecular biomarkers capable of predicting resistance to this therapy. Thus, the use of machine learning techniques, together with transcriptome analyses could contribute to the management of oncological treatments for this stage of the disease.
Methods
We included 118 samples corresponding to patients classified in the Luminal A, Luminal B, HER2, and Triple Negative subtypes in locally advanced stages who did not present metastasis or had not received treatment at the time of biopsy in the period 2012 - 2015. RNA was extracted from fresh tumor biopsies prior to the administration of neoadjuvant chemotherapy. After obtaining the results of the clinical monitoring of response to the treatment, the patient samples were grouped as "control" if they presented complete pathological response to the treatment, and "case" if they presented resistance. Subsequently, the total RNA of the samples was processed by massive RNA sequencing (RNA-seq) and a differential expression analysis was performed using DESeq2. Finally, machine learning algorithms were used to select a group of genes capable of classifying patients into "resistant" and "non-resistant" and a panel of response biomarkers was proposed.
Results
A set of mRNAs and lncRNAs capable of discriminating the outcome of breast cancer patients to neoadjuvant chemotherapy as well as the enriched pathways associsted with them was identified.
Conclusions
We propose a preliminary biomarker panel, wich will later be tested and validated in large, well-designed, prospective clinical trials. The validation of molecular biomarkers and their eventual incorporation into clinical practice will improve personalized cancer treatments and the management of advanced stages.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Instituto Nacional de Cancerología INCan (018/055/DII) (CEI/1302/18).
Funding
Instituto Nacional de Cancerología INCan (018/055/DII) (CEI/1302/18).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
158P - Enhancing the communication of genomic results: Understanding patient and clinician perspectives
Presenter: Eleanor Johnston
Session: Cocktail & Poster Display session
Resources:
Abstract
159P - Precision medicine-based platform to guide the treatment of EML4-ALK fusion lung cancers and other NSCLC
Presenter: Nathan Merrill
Session: Cocktail & Poster Display session
Resources:
Abstract
160P - CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 inhibitors
Presenter: Margaux BETZ
Session: Cocktail & Poster Display session
Resources:
Abstract
161P - PDL1 expression and its relation to EML4-ALK gene variants in metastatic lung adenocarcinoma: A single-center real-world experience
Presenter: Santhosh Meedimale
Session: Cocktail & Poster Display session
Resources:
Abstract
163P - Impact of genomic sequencing data on treatment decisions in advanced breast cancer (ABC)
Presenter: Sviatoslav Chekhun
Session: Cocktail & Poster Display session
Resources:
Abstract
164P - Clinical utility of comprehensive molecular profiling tests for advanced gastrointestinal tumors
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
165P - Evaluation of the mutational profile in patients with metastatic non-small cell lung carcinoma diagnosed in a tertiary hospital which was performed by NGS method
Presenter: Kankan Deka
Session: Cocktail & Poster Display session
Resources:
Abstract
166P - Targeted next-generation sequencing as reliable detection of genetic profile for cancer treatment to guide oncologists in Pakistan
Presenter: Zeeshan Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
167P - Molecular analysis of gastrointestinal stromal tumor (GIST): The experience of Regina Elena National Cancer Institute
Presenter: Andrea Torchia
Session: Cocktail & Poster Display session
Resources:
Abstract
168P - Usefulness of liquid biopsy in the management of patients with advanced or metastatic pancreatic cancer
Presenter: Jorge Iranzo Barreira
Session: Cocktail & Poster Display session
Resources:
Abstract